Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Common Stock · Q4 FY2025 · quarter ended Dec 2025
Common stock broadly unchanged from a year ago
Common stock stood at $14.39K at the end of Q4 FY2025, up 1.1% from a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +1.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 14.39K USD
- Year-over-year change
- +1.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.39K | +1.1% |
| FY2024 | 2024-12-31 | 14.23K | +0.0% |
| FY2023 | 2023-12-31 | 14.23K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Common Stock vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.1% is the 4th highest of 10, against a peer median of +0.0%.
- Common stock amounts to 0.0% of total assets for NNNN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$2.27B CAD | -1.0% | +0.3% | 173.0% | |
| Mar 2026 | $1.39M USD | +48.5% | +30.3% | 0.3% | |
| Mar 2026 | $1M USD | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $500K USD | +0.0% | +0.0% | 0.0% | |
| Feb 2026 | $387K USD | +0.5% | +0.4% | 0.1% | |
| Mar 2026 | $300K USD | +7.1% | +6.1% | 0.3% | |
| Dec 2025 | $51K USD | — | — | 0.0% | |
| Mar 2026 | $24K USD | +4.3% | +33.9% | 0.0% | |
| Mar 2026 | $18K USD | +0.0% | -53.1% | 0.0% | |
| Mar 2026 | $17K USD | +0.0% | +2.0% | 0.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $14.39K USD | +1.1% | — | 0.0% |
| Peer median (excluding NNNN) | — | +0.0% | +0.4% | 0.0% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.